Products for the treatment of inflammatory bowel disease: a patent review (2013-2014)

Página do item simplificado
dc.contributor.authorDi Stasi, Luiz C. [UNESP]
dc.contributor.authorCosta, Celso A. R. A. [UNESP]
dc.contributor.authorWitaicenis, Aline [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-10-21T13:11:05Z
dc.date.available2015-10-21T13:11:05Z
dc.date.issued2015-06-01
dc.description.abstractIntroduction: Inflammatory bowel disease (IBD) consists of Crohn's disease, ulcerative colitis and an unspecific IBD. The unclear etiology of IBD is a limiting factor that complicates the development of new pharmacological treatments and explains the high frequency of refractory patients to current drugs, including both conventional and biological therapies. In view of this, recent progress on the development of novel patented products to treat IBD was reviewed.Areas covered: Evaluation of the patent literature during the period 2013 - 2014 focused on chemical compounds, functional foods and biological therapy useful for the treatment of IBD.Expert opinion: Majority of the patents are not conclusive because they were based on data from unspecific methods not related to intestinal inflammation and, when related to IBD models, few biochemical and molecular evaluations that could be corroborating their use in human IBD were presented. On the other hand, methods and strategies using new formulations of conventional drugs, guanylyl cyclase C peptide agonists, compounds that influence anti-adhesion molecules, mAbs anti-type I interferons and anti-integrin, oligonucleotide antisense Smad7, growth factor neuregulin 4 and functional foods, particularly fermented wheat germ with Saccharomyces cerevisiae, are promising products for use in the very near future.en
dc.description.affiliationUnespSão Paulo State University (UNESP), Institute of Biosciences, Department of Pharmacology, Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech), 18.618-000 - Botucatu, São Paulo, Brazil
dc.description.affiliationUnespSão Paulo State University (UNESP), Institute of Biosciences, Department of Pharmacology, Laboratory of Phytomedicines, Pharmacology and Biotechnology (PhytoPharmaTech), 18.618-000 - Botucatu, São Paulo, Brazil.
dc.format.extent629-642
dc.identifierhttp://www.tandfonline.com/doi/full/10.1517/13543776.2015.1041921
dc.identifier.citationExpert Opinion On Therapeutic Patents. London: Informa Healthcare, v. 25, n. 6, p. 629-642, 2015.
dc.identifier.doi10.1517/13543776.2015.1041921
dc.identifier.issn1354-3776
dc.identifier.urihttp://hdl.handle.net/11449/128570
dc.identifier.wosWOS:000354951400002
dc.language.isoeng
dc.publisherInforma Healthcare
dc.relation.ispartofExpert Opinion On Therapeutic Patents
dc.relation.ispartofjcr2.867
dc.relation.ispartofsjr0,926
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectColitisen
dc.subjectCrohn’s diseaseen
dc.subjectFunctional foodsen
dc.subjectInflammatory bowel diseaseen
dc.subjectIntestinal anti-inflammatory compoundsen
dc.subjectmAben
dc.subjectNatural productsen
dc.subjectRebioticen
dc.subjectProbioticen
dc.titleProducts for the treatment of inflammatory bowel disease: a patent review (2013-2014)en
dc.typeResenha
dcterms.licensehttp://informahealthcare.com/userimages/ContentEditor/1255620309227/Copyright_And_Permissions.pdf
dcterms.rightsHolderInforma Healthcare
unesp.author.orcid0000-0002-7864-1073[1]
unesp.campusUniversidade Estadual Paulista (Unesp), Instituto de Biociências, Botucatupt

Arquivos

Coleções

Artigos - Farmacologia - IBB